A:

The drugs sector is the portion of industry that develops and produces pharmaceuticals. This sector includes both major corporations and small startup companies that research, create and manufacture drugs for therapeutic use. The pharmaceutical industry is characterized by substantial research and development costs and is heavily regulated by world governments. In the United States, the Food and Drug Administration (FDA) is responsible for ensuring that only drugs with beneficial therapeutic use and reasonable side effects are brought to market.

As a result of this regulation, pharmaceutical companies must be able to sustain themselves financially through long periods of investigation and testing before their products may be legally sold. This means companies and industry investors are accustomed to long timetables and thorough and expensive evaluation processes for new products. To remain profitable, these companies must have strong revenue streams from products currently on the market, must partner with larger companies, or must be able to secure generous loans and investor financing.

In this industry, small startup companies account for a substantial portion of new drug development. These companies frequently pursue specific treatments that don't yet exist. A new business may have only one or two key drugs under development in its product pipeline at one time. These new drugs require approximately 10 to 15 years of research and FDA supervision financed by the starting capital of early investors. Many companies soon seek a buyer or merger with a larger company that has the necessary capital and expertise to guide the new product into the marketplace.

Larger drug manufacturers often acquire a substantial amount of their total pipelines using this means. Mergers and acquisitions (M&As) move many new drugs through the regulatory environment and provide a means for major pharmaceutical corporations to obtain new drugs for their product lines. Using this strategy, larger companies can wait for new pharmaceuticals to show potential during testing before risking investment capital. At some point during the testing phases, companies looking for potential new acquisitions begin conversations with the startup's management team. Before reaching a point in research when the company can begin fielding offers, the new company may need one or more rounds of funding.

When a company finally receives approval and begins distributing a new drug, patents protect the product from competition and allow it to find a profitable niche in the market. The legal and exclusive rights to producing a successful drug represent a substantially valuable piece of intellectual property for pharmaceutical companies. Patented drugs are potentially much more profitable than the production of generic drugs. This profitability motivates the development of new treatments and is the bread-and-butter of the pharmaceutical industry. A strategic product line of patented drugs, generics and new potential drugs can generate substantial profits for many companies in the drug industry.

RELATED FAQS
  1. What are the primary risks associated with investing in the drugs sector?

    Learn more about the primary risks facing investors in the pharmaceutical and biotechnology industries. Find out how regulation ... Read Answer >>
  2. How does government regulation impact the drugs sector?

    Learn about how drugs are regulated by the U.S. government as well as the role of the Food and Drug Administration during ... Read Answer >>
  3. How does the profit margin compare for a generic drug versus a brand name drug?

    Learn how the profit margins compare for generic drugs and brand-name drugs. Brand-name drugs cost three to four times more ... Read Answer >>
  4. What are the major barriers to entry for new companies in the drugs sector?

    Find out why barriers to entry for U.S. drug companies are so high and how the Food and Drug Administration, or FDA, inhibits ... Read Answer >>
  5. What are the primary factors that drive share prices in the drugs sector?

    Learn about the primary factors that drive share prices in the drug sector. Creating and manufacturing drugs is a complex ... Read Answer >>
  6. What are the differences between brand name drugs and generic drugs?

    Discover the process by which brand name drugs lose their patent, allowing generics to be manufactured, as well as the differences ... Read Answer >>
Related Articles
  1. Insights

    The Industry Handbook: Pharma Industry

    Learn about the pharmaceutical industry and discover the forces that influence this highly profitable and dynamic sector.
  2. Investing

    Drug Approvals Fell to Six-Year Low in 2016

    New drug approvals dropped to modest levels in 2016 following highs in 2014 and 2015.
  3. Investing

    Where Does the US Get Its Supply of Drugs?

    Despite increasing demands for local production, the US imports only a small portion of its drugs.
  4. Investing

    3 of America's Most Expensive Drugs and Who Profits From Them

    Learn about orphan drugs that are some of the most expensive drugs in America. Read about the companies that manufacture these drugs.
  5. Investing

    Drug Prices: Name Brands Doubled in Last 5 Years (ESRX)

    Express Scripts' Drug Trends Report, released Monday, revealed that the average price of brand name drugs rose 16.2% in 2015, with over one third of brand name drugs seeing price increases over ...
  6. Insights

    8 Stages Of New Drug Development

    Understanding biotech data isn't easy. What is a clinical trial, what are the various phases, and why do the results of these trials and applications often create double-digit moves in the price ...
  7. Investing

    Cost of Old Cancer Drugs Rises in EU Amid Outcry

    The prices of several off-patent cancer drugs have soared more than 100% in Europe.
  8. Investing

    Drug Supply Chain May Be Driver of High Drug Prices

    Non-manufacturing stakeholders in the drug pricing system are the ones contributing to high prices.
  9. Insurance

    Big Pharma: Will Price Pressure Happen No Matter What?

    Watch out for a possible decline in pharmaceutical stock prices, thanks to a renewed debate about the role of government policy and macroeconomic headwinds.
RELATED TERMS
  1. Abbreviated New Drug Application (ANDA)

    A written request to the U.S. Food and Drug Administration to ...
  2. Orange Book

    A list of drugs that the U.S. Food and Drug Administration has ...
  3. Food And Drug Administration - FDA

    A government agency established in 1906 with the passage of the ...
  4. Bioequivalence

    A similarity between two drugs meaning that they both have the ...
  5. Orphan Drug

    A drug or biological product that treats a rare condition or ...
  6. Phase 2

    The second phase of clinical trials or studies for an experimental ...
Hot Definitions
  1. Donchian Channels

    A moving average indicator developed by Richard Donchian. It plots the highest high and lowest low over the last period time ...
  2. Consumer Price Index - CPI

    A measure that examines the weighted average of prices of a basket of consumer goods and services, such as transportation, ...
  3. Moving Average - MA

    A moving average (MA) is a widely used indicator in technical analysis that helps smooth out price action by filtering out ...
  4. Stop Order

    A stop order is an order to buy or sell a security when its price increases past a particular point in order to limit losses ...
  5. Inflation

    The rate at which the general level of prices for goods and services is rising and, consequently, the purchasing power of ...
  6. Candlestick

    A chart that displays the high, low, opening and closing prices for a security for a single day. The wide part of the candlestick ...
Trading Center